Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers

SMT C1100 is a small molecule utrophin modulator in development to treat Duchenne muscular dystrophy. This study evaluated the safety, tolerability, and pharmacokinetics of SMT C1100 in healthy volunteers. This double‐blind, placebo‐controlled Phase 1 study comprised: Part 1, an escalating, single‐d...

Descripción completa

Detalles Bibliográficos
Autores principales: Tinsley, Jon, Robinson, Neil, Davies, Kay E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024067/
https://www.ncbi.nlm.nih.gov/pubmed/25651188
http://dx.doi.org/10.1002/jcph.468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024067/
https://www.ncbi.nlm.nih.gov/pubmed/25651188
http://dx.doi.org/10.1002/jcph.468

Ejemplares similares